Abordagens diagnósticas, terapêuticas e prognósticas no mastocitoma canino de grau II e III.
DOI:
https://doi.org/10.63325/bjahh.2024.37Palavras-chave:
mastocitoma, oncologia, neoplasia cutânea, tratamentoResumo
O mastocitoma cutâneo é o segundo tumor mais comum em cães, representando de 16% a 21% das neoplasias malignas. A cirurgia é a abordagem preferencial, mas em diversos casos é necessária a intervenção com terapias diversas. Apesar de diversos estudos disponíveis, ainda não há consenso sobre qual tratamento é mais eficaz ou quais prognósticos devem ser levados em consideração para acompanhar o desenvolvimento da doença. Diante desse cenário, este trabalho visa descrever abordagens terapêuticas e prognósticos relevantes relacionados ao mastocitoma canino de grau II e III e sintetizar evidências sobre as melhores práticas terapêuticas e informações prognósticas no manejo desses tumores, contribuindo para um melhor entendimento e tratamento do mastocitoma cutâneo em cães.
Referências
AMAGAI, Y. Et al. Production of stem cell factor in canine mast cell tumors. Research in veterinary science. v. 96, n.1, p. 124-126, fev. 2014. Disponível em: https://doi.org/10.1016/j.rvsc.2013.10.014 Acesso em 18 ago. 2024
BAGINSKI, H.; DAVIS, G.; BASTIAN, R. P. The Prognostic Value of Lymph Node Metastasis with Grade 2 MCTs in Dogs: 55 Cases (2001-2010). Journal of the American Animal Hospital Association, v. 50, n. 2, p. 89–95, abr. 2014. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24446400/ Acesso em 18 ago. 2024.
BLACKWOOD, L et al. European Consensus Document on Mast Cell Tumours in Dogs and Cats. Veterinary and comparative oncology, v. 10, n. 3, p. e1–e29, set. 2012. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/j.1476-5829.2012.00341.x Acesso em 18 ago. 2024.
COWELL, R.L.; TYLER, R.D.; MEINKOTH, J.H.; DENICOLA, D.B. Diagnóstico citológico e hematologia de cães e gatos. Medvet. São Paulo 2009, 69–77.
DE NARDI, A. B et al. Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors. Cells, v. 11, n. 4, 10 fev. 2022. Disponível em: https://doi.org/10.3390/cells11040618 Acesso em 18 ago. 2024.
DONNELY, L. Et al. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. Veterinary and Comparative Oncology, v. 13, n. 1, p. 70-76, mar. 2015. Disponível em:
https://doi.org/10.1111/vco.12021 Acesso em 18 ago. 2024
DOWNING S. Et al. Prevalence and significance of internal tandem duplications in exons 11 and 12 of C-kit in mast cell tumors of dogs. American Journal of veterinary research. v. 63. n. 12, 2022. Disponível em: https://avmajournals.avma.org/view/journals/ajvr/63/12/ajvr.2002.63.1718.xml Acesso em 23 ago. 2024
ELLIOTT, J. W et al. Canine Oral Mucosal Mast Cell Tumours. Veterinary and comparative oncology, v. 14, n. 1, p. 101–111, mar. 2016. Disponivel em: https://onlinelibrary.wiley.com/doi/10.1111/vco.12071 Acesso em 23 ago. 2024.
ELSTON, L. B. Et al. Letter to the Editor: The Importance of the Mitotic Index as a Prognostic Factor for Survival of Canine Cutaneous Mast Cell Tumors: A Validation Study. Veterinary Pathology, v. 46, n. 2, p. 362–364, mar. 2009. Disponível em: https://doi.org/10.1354/vp.46-2-362 Acesso em 23 ago. 2024.
HAHN, K. A. et al. Evaluation of 12- and 24-Month Survival Rates after Treatment with Masitinib in Dogs with Nonresectable Mast Cell Tumors. American journal of veterinary research, v. 71, n. 11, p. 1354–1361, nov. 2010. Disponivel em: https://doi.org/10.2460/ajvr.71.11.1354 Acesso em 18 ago. 2024
HAHN, K. A et al. Masitinib Is Safe and Effective for the Treatment of Canine Mast Cell Tumors. Journal of veterinary internal medicine, v. 22, n. 6, p. 1301–1309, dez. 2008. Disponivel em: https://doi.org/10.1111/j.1939-1676.2008.0190.x Acesso em 23 ago. 2024
HUME CT, KIUPEL M, RIGATTI L, ET AL. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997–2007). J Am Anim Hosp Assoc. v. 47, n 1, p. 37-44, 2011. Disponivel em: https://doi.org/10.5326/JAAHA-MS-5557 Acesso em 23 ago. 2024
KARBE, G. T. et al. Evaluation of Scar Revision after Inadequate Primary Excision of Cutaneous Mast Cell Tumors in 85 Dogs (2000-2013). Veterinary surgery: VS, v. 50, n. 4, p. 807–815, maio 2021. Disponivel em: https://doi.org/10.1111/vsu.13619 Acesso em 18 ago. 2024
KIUPEL, M. et al. Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior. Veterinary Pathology, v. 48, n. 1, p. 147–155, jan. 2011. Disponivel em: https://doi.org/10.1177/030098581038646 Acesso em 23 ago. 2024
KIUPEL, M.; WEBSTER, J. D.; MILLER, R. A.; KANEENE, J. B. Impact of Tumour Depth, Tumour Location and Multiple Synchronous Masses on the Prognosis of Canine Cutaneous Mast Cell Tumours. Journal of veterinary medicine. A, Physiology, pathology, clinical medicine, v. 52, n. 6, p. 280–286, ago. 2005. Disponivel em:
https://doi.org/10.1111/j.1439-0442.2005.00726.x Acesso em 18 ago. 2024
LEMARIE R, LEMARIE SL, HEDLUND CS. Mast cell tumors: clinical management. Comp. Cont. Ed. Prac. Vet. v. 17, n. 9, p.1085–1090, 1995. Disponível em: https://inis.iaea.org/search/searchsinglerecord.aspx?recordsFor=SingleRecord&RN=45089361 Acesso em 23 ago. 2024
LINDE, K. J.; STOCKDALE, S. L.; MISON, M. B.; PERRY, J. A. The Effect of Prednisone on Histologic and Gross Characteristics in Canine Mast Cell Tumors. The Canadian veterinary journal = La revue veterinaire canadienne, v. 62, n. 1, p. 45–50, jan. 2021. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC7739397/ Acesso em 18 ago. 2024
LONDON C. A. et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology, v. 27, n. 4, p. 689-697, abr. 1999. Disponível em: https://doi.org/10.1016/S0301-472X(98)00075-7 Acesso em 23 ago. 2024
LONDON, C. A. Et al. Multi-Center, Placebo-Controlled, Double-Blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision. Clinical cancer research: an official journal of the American Association for Cancer Research, v. 15, n. 11, p. 3856–3865, 1 jun. 2009. Disponível em: https://doi.org/10.1158/1078-0432.CCR-08-1860 Acesso 18 ago. 2024
LONDON, C. A. & SEGUIN, B. Mast cell tumors in the dog. Veterinary Clinics of North America: Small Animal Practice, v. 33, n. 3, p. 473-489, mai. 2003. Disponível em: https://doi.org/10.1016/S0195-5616(03)00003-2 Acesso em 18 ago. 2024
LOWE, R. Et al. The Treatment of Canine Mast Cell Tumours with Electrochemotherapy with or without Surgical Excision. Veterinary and comparative oncology, v. 15, n. 3, p. 775–784, set. 2017. Disponível em: https://doi.org/10.1111/vco.12217 Acesso em 18 ago. 2024
MACEDO, T. R. Et al. Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. Cells, v. 11, n. 3, p. 571, fev. 2022. Disponível em: https://doi.org/10.3390/cells11030571 Acesso em 23 ago. 2024
MARCONATO L. Et al. Clinicopathological features and outcome for dogs with mast cell tumours and bone marrow involvement. Journal of Veterinary Internal Medicine, v. 22, n. 4, p. 1001-1007, jul. 2008. Disponível em: https://doi.org/10.1111/j.1939-1676.2008.0128.x Acesso em 18 ago. 2024
MARCONATO L. Et al. Morphometrical approach for predicting regional lymph node micrometastatic load in canine mast cell tumours: preliminary results. Veterinary and Comparative Oncology, v. 6, n. 3, p. 162–170, set. 2008. Disponível em: https://doi.org/10.1111/j.1476-5829.2008.00157.x Acesso em 23 ago. 2024
MARCONATO, L. Et al. Subcutaneous Mast Cell Tumours: A Prospective Multi-Institutional Clinicopathological and Prognostic Study of 43 Dogs. The Veterinary record, v. 193, n. 1, p. e2991, 8 jul. 2023. Disponível em: https://doi.org/10.1002/vetr.2991 Acesso em 23 ago. 2024
MASON, S. L. Et al. Outcomes of adjunctive radiation therapy for the treatment of mast cell tumors in dogs and assessment of toxicity: A multicenter observational study of 300 dogs. Journal of veterinary internal medicine, v. 35, n. 6, p. 2853-2864, nov. 2021. Disponível em: https://doi.org/10.1111/jvim.16264 acesso em 18 ago. 2024
MILLER, R. L. Et al. A Retrospective Review of Treatment and Response of High-Risk Mast Cell Tumours in Dogs. Veterinary and comparative oncology, v. 14, n. 4, p. 361–370, dez. 2014. Disponível em: https://doi.org/10.1111/vco.12116 Acesso em 23 ago. 2024
MULLINS, M. N. Et al. Evaluation of Prognostic Factors Associated with Outcome in Dogs with Multiple Cutaneous Mast Cell Tumors Treated with Surgery with and without Adjuvant Treatment: 54 Cases (1998-2004). Journal of the American Veterinary Medical Association, v. 228, n. 1, p. 91–95, jan. 2006. Disponível em: https://doi.org/10.2460/javma.228.1.91 Acesso em 18 ago. 2024
MURPHY S. Et al. Effects of stage and number of tumours on prognosis of dogs with cutaneous MCTs. The Veterinary Record, v. 158, n. 9, p. 287-291, mar. 2006. Disponível em: https://doi.org/10.1136/vr.158.9.287 Acesso em 18 ago. 2024
NATIVIDADE, F. S. Et al. Análise de sobrevida e fatores prognósticos de cães com mastocitoma cutâneo. Pesq. Vet. Bras, v. 34, n. 9, p. 874-884, set. 2014. Disponível em: https://doi.org/10.1590/S0100-736X2014000900012 Acesso em 18 ago. 2024
NORTHRUP, N. C. Et al. Variation among Pathologists in the Histologic Grading of Canine Cutaneous Mast Cell Tumors with Uniform Use of a Single Grading Reference. Journal of Veterinary Diagnostic Investigation, v. 17, n. 6, p. 561–564, nov. 2005. Disponível em: https://doi.org/10.1177/104063870501700606 Acesso em 18 ago. 2024
OLSEN, J. A. Et al. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Veterinary medicine and science, v. 4, n. 3, p. 237-251, ago. 2018. Disponível em: https://doi.org/10.1002/vms3.106 Acesso em 23 ago. 2024
OSSOWSKA, M. Et al. Pre-operative neoadjuvant vinblastine-prednisolone in canine mast cell tumours: A single-centre retrospective cohort study. Veterinary and comparative oncology, v. 21, n. 3, p. 447-459, set. 2023. Disponível em: https://doi.org/10.1111/vco.12904 Acesso em 23 ago. 2024
PATNAIK, A. K.; EHLER, W. J.; MACEWEN, E. G. Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs. Veterinary Pathology, v. 21, n. 5, p. 469–474, set. 1984. Disponível em: https://doi.org/10.1177/030098588402100503 Acesso em 18 ago. 2024
RASSNICK K.M. Et al. Treatment of canine mast cell tumours with CCNU (lomustine). Journal of Veterinary Internal Medicine, v. 13, n. 6, p.601-605, nov. 1999. Disponível em: https://doi.org/10.1111/j.1939-1676.1999.tb02217.x Acesso em 18 ago. 2024
RASSNICK, K. M. Et al. A Phase II Study to Evaluate the Toxicity and Efficacy of Alternating CCNU and High-Dose Vinblastine and Prednisone (CVP) for Treatment of Dogs with High-Grade, Metastatic or Nonresectable Mast Cell Tumours. Veterinary and comparative oncology, v. 8, n. 2, p. 138–152, jun. 2010. Disponível em:
https://doi.org/10.1111/j.1476-5829.2010.00217.x Acesso em 18 ago. 2024
REGUERA, M. J. Et al. Canine Mast Cell Tumors Express Stem Cell Factor Receptor. The American Journal of Dermatopathology. v.22, n.1, p 49-54, fev. 2000 Disponível em: https://journals.lww.com/amjdermatopathology/abstract/2000/02000/canine_mast_cell_tumors_express_stem_cell_factor.10.aspx Acesso em: 18 ago. 2024
RIBEIRO P.R. Et al. Pathological aspects of cutaneous mast cell tumors with metastases in 49 dogs. Veterinary Pathol. v. 59, n. 6, p. 922-930, jul. 2022. Disponível em: https://doi.org/10.1177/03009858221114468 Acesso em 18 ago. 2024
ROMANSIK E.M. Et al. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol. v. 44, n. 3, p. 335-341, mai. 2007. Disponível em: https://doi.org/10.1354/vp.44-3-335 Acesso em 18 ago. 2024
TAKAHASHI T. Et al. Visceral mast cell tumors in dogs: 10 cases (1982–1997). JAVMA, v. 216, n. 2, p. 222-226, jan. 2000. Disponível em: https://doi.org/10.2460/javma.2000.216.222 Acesso em 18 ago. 2024
THAMM DH, TUREK MM AND VAIL DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. The Journal of of Veterinary Medical Science, v. 68, n. 6, p. 581-587, 2006. Disponível em: https://doi.org/10.1292/jvms.68.581 Acesso em 23 ago. 2024
THAMM D.H.; MAUDLIN E. A. AND VAIL D.M. Prednisolone and vinblastine chemotherapy for canine mast cell tumor – 41 cases (1992–97). Journal of Veterinary Internal Medicine, v.13, n. 5, p. 491-497, set. 1999. Disponível em: https://doi.org/10.1111/j.1939-1676.1999.tb01468.x Acesso em 23 ago. 2024
THAMM, D. H.; WEISHAAR, K. M.; CHARLES, J. B.; EHRHART, E. J. 3rd. Phosphorylated KIT as a Predictor of Outcome in Canine Mast Cell Tumours Treated with Toceranib Phosphate or Vinblastine. Veterinary and comparative oncology, v. 18, n. 2, p. 169–175, jun. 2020. Disponível em: https://doi.org/10.1111/vco.12525 Acesso em 18 ago. 2024
VAIL, D. M. Et al. Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs. Journal of veterinary internal medicine, v. 26, n. 3, p. 598–607, jun. 2012. Disponível em: https://doi.org/10.1111/j.1939-1676.2012.00897.x Acesso em 18 ago. 2024
VICKERY KR, WILSON H, VAIL DM AND THAMM DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Veterinary and Comparative Oncology. v. 6, n. 2, p. 111–119, jun. 2008. Disponível em: https://doi.org/10.1111/j.1476-5829.2007.00147.x Acesso em 18 ago. 2024
WEISHAAR, K. M. Et al. C-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. Journal of veterinary internal medicine, v. 32, n. 1, p. 394–405, jan. 2018. Disponível em: https://doi.org/10.1111/jvim.14889 Acesso em 18 ago. 2024
WELLE, M. M.; BLEY, C. R.; HOWARD, J.; RÜFENACHT, S. Canine Mast Cell Tumours: A Review of the Pathogenesis, Clinical Features, Pathology and Treatment. Veterinary dermatology, v. 19, n. 6, p. 321–339, dez. 2008. Disponível em: https://doi.org/10.1111/j.1365-3164.2008.00694.x Acesso em 18 ago. 2024
WILLMANN, M. Et al. Comparative Oncology: The Paradigmatic Example of Canine and Human Mast Cell Neoplasms. Veterinary and comparative oncology, v. 17, n. 1, p. 1–10, mar. 2019. Disponível em: https://doi.org/10.1111/vco.12440 Acesso em 18 ago. 2024
WORLEY, D. R. Incorporation of Sentinel Lymph Node Mapping in Dogs with Mast Cell Tumours: 20 Consecutive Procedures. Veterinary and comparative oncology, v. 12, n. 3, p. 215–226, set. 2014. Disponível em: https://doi.org/10.1111/j.1476-5829.2012.00354.x Acesso em 18 ago. 2024
ZEMKE D, YAMINI B, YUZBASIYAN-GURKAN V. Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the proto-oncogene c-KIT. J Vet Diagn Invest. P. 341-345, 2001. Disponível em: https://doi.org/10.1177/104063870101300411 Acesso em 18 ago. 2024
